Lilly Eli & (LLY) Stock News

Eli Lilly (NYSE: LLY) will present data from multiple oncology studies at the 2025 ASCO Annual Meeting (May 30-June 3, Chicago). Key presentations include: 1. Imlunestrant: Patient-reported outcomes and safety analyses from Phase 3 EMBER-3 trial in ER+/HER2- advanced breast cancer 2. Olomorasib: Updated results from Phase 1/2 studies combining this KRAS G12C inhibitor with: - Pembrolizumab in NSCLC - Cetuximab in colorectal cancer 3. LY4170156: Initial results from Phase 1a/1b study of this FRα-targeting antibody-drug conjugate in platinum-resistant ovarian cancer 4. Verzenio: Analysis of BMI impact on efficacy and safety in breast cancer patients from the monarchE trial

Eli Lilly's Kisunla (donanemab) has received marketing authorization in Australia for treating early symptomatic Alzheimer's disease in adults who are ApoE ε4 heterozygotes or non-carriers. This marks the 13th regulatory authorization globally for the drug.

Key clinical results from the TRAILBLAZER-ALZ 2 Phase 3 study showed that Kisunla:

• Slowed cognitive and functional decline by up to 35% compared to placebo at 18 months
• Reduced disease progression risk by 39% over the same period

The drug targets amyloid plaques and is notable as the only amyloid-targeting therapy with evidence supporting treatment discontinuation once plaques are removed. Of the estimated 600,000 Australians living with Alzheimer's, approximately 450,000 in early stages could be assessed for Kisunla treatment eligibility.

Eli Lilly's Zepbound (tirzepatide) demonstrated superior weight loss results compared to Wegovy (semaglutide) in the Phase 3b SURMOUNT-5 trial. After 72 weeks, Zepbound patients achieved an average weight reduction of 20.2% compared to 13.7% with Wegovy, representing a 47% greater relative weight loss. Zepbound patients lost an average of 50.3 lbs versus 33.1 lbs with Wegovy. The trial met all primary and secondary endpoints, with 64.6% of Zepbound patients achieving at least 15% weight loss compared to 40.1% for Wegovy. Zepbound also showed superior waist circumference reduction of 7.2 inches versus 5.1 inches for Wegovy. The safety profile was consistent with previous trials, with mainly mild to moderate gastrointestinal-related adverse events.

Eli Lilly (NYSE: LLY) announced plans to invest up to $250 million in an expanded collaboration with Purdue University over the next eight years, potentially becoming the largest industry-academic agreement in U.S. history. The Lilly-Purdue 360 Initiative, extending through 2032, aims to accelerate pharmaceutical innovation across the entire pipeline.

The partnership will focus on key areas including: AI-powered drug discovery, technology-enabled treatment acceleration, manufacturing optimization through robotics and AI, and workforce development. The collaboration includes on-site research opportunities at both institutions and builds on existing programs like Lilly Scholars and the Lilly and Purdue Research Alliance Center (LPRC).

Eli Lilly (NYSE: LLY) announced key executive leadership changes to support its continued growth trajectory. Ilya Yuffa, currently EVP and president of Lilly International, will become EVP and president of Lilly USA and Global Customer Capabilities, leading U.S. operations and product launches. Patrik Jonsson, current EVP and president of Lilly Cardiometabolic Health and Lilly USA, will transition to EVP and president of Lilly International, overseeing all non-U.S. markets. Kenneth Custer, Ph.D., currently GM of Lilly Canada, will be promoted to EVP and president of Lilly Cardiometabolic Health and join the executive committee. These changes aim to enhance the company's focus on U.S. business and global therapeutic areas amid significant growth in cardiometabolic health and U.S. operations.

Eli Lilly (NYSE:LLY) has announced its quarterly dividend payment for Q2 2025. The company's board of directors has declared a dividend of $1.50 per share on outstanding common stock. The dividend will be paid on June 10, 2025, to shareholders who are on record as of the close of business on May 16, 2025.

Scribe Therapeutics announced its participation in the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, scheduled for May 13-17, 2025, in New Orleans. The company will present two significant developments: First, data on their X-Editor (XE) technology for treating Duchenne Muscular Dystrophy (DMD), showcasing its potential for inherited muscle disorders. Second, a joint presentation with Prevail Therapeutics, a Lilly subsidiary, demonstrating their collaboration on self-inactivating AAV vectors combined with CRISPR-based XE technology, which showed effective in vivo editing in mice's central nervous system. The companies recently achieved a milestone in their partnership focusing on neurological and neuromuscular diseases.

Eli Lilly (NYSE:LLY) announced its participation in the upcoming Bank of America Securities 2025 Healthcare Conference on May 15, 2025. The company's executive vice president and CFO, Lucas Montarce, will participate in a fireside chat at 11:40 a.m. Eastern time.

Investors can access a live audio webcast of the presentation through Lilly's investor website, with a replay available for approximately 90 days following the event.

Eli Lilly (LLY) reported strong Q1 2025 financial results with revenue increasing 45% to $12.73 billion, primarily driven by Mounjaro and Zepbound sales. Earnings per share (EPS) grew 23% to $3.06 on a reported basis and 29% to $3.34 on a non-GAAP basis. Key highlights include: • Mounjaro revenue surged 113% to $3.84 billion • Zepbound revenue reached $2.31 billion • Verzenio revenue grew 10% to $1.16 billion The company achieved positive Phase 3 trial results for orforglipron, their oral GLP-1 agonist for Type 2 diabetes. Lilly reaffirmed its 2025 revenue guidance of $58.0-61.0 billion and updated EPS guidance to $20.17-21.67 (reported) and $20.78-22.28 (non-GAAP). The company plans to double U.S. manufacturing investment to over $50 billion since 2020.